Another cap for imported insulin; domestic manufacturers cry foul.
FinMin had objected and wanted existing cost-plus method retained.
CCI to examine competition part of deals, RBI prudential aspects.
Work to begin after that on corrective measures to meet US regulator's requirements.
USFDA has extended the timeline for granting tentative approval to generic drug applications filed under Para IV of its rules by 10 months.
Sun Pharma could have to withdraw cancer drug as J&J re-enters after temporary eclipse
Now, the companies need to get National Pharmaceutical Pricing Authority's nod for changing medicine composition. If they flout norms, government will take penal action.
GoM had proposed a new pricing mechanism, but judges had said at an earlier hearing the current formula should stay.
Ranbaxy was scheduled to launch its drug on September 21, the day Diovan's patent expired.
The move is significant, as this may prompt investigating agencies to take a look at the fresh accounting statements to be filed by the company to RoC, before taking a final call.
It was in 2005, India changed its patent law and started granting patents in medicines.
The prices of essential medicines may drop, as the National Pharmaceutical Pricing Authority (NPPA) has made significant changes in its norms to rationalise price approvals.
Orders surprise inspections at chemists and pharma stores.
CCI, sector regulators may consult each other if jurisdictions overlap
Moolchand Healthcare Pvt Ltd, the corporate entity formed by the group in 2006 with expansion in mind, is on an acquisition spree for hospital chains, IVF (in vitro fertilisation) clinics and pathological laboratories.
This helps consumers check the authenticity of drugs simply by sending SMSes.
Financial pressure on the parent company triggered the move.
Import alert on unit-6 facility might be lifted by FDA by Sept.
Reebok's staff to get voluntary retirement option, stores may be reduced by a third.
Drug maker Cipla Ltd is rejigging its China business. The pharma company recently exited a significant part of its investment in its Chinese partner Desano Holdings, while ploughing back a part of the funds into the group's units manufacturing biosimilars and active pharmaceutical ingredients (APIs).
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances